Label: information for the user
Aricept Flas 10 mg buccal tablets
Donepezil hydrochloride
Read this label carefully before starting to take this medication, as it contains important information for you
Aricept Flas belongs to a group of medications called acetylcholinesterase inhibitors. Donepezil hydrochloride increases the levels in the brain of a substance related to memory (acetylcholine) by reducing the rate of breakdown of this substance.
It is used for the treatment of mild to moderately severe symptoms of Alzheimer's disease. Symptoms include increased memory loss, confusion, and changes in behavior.
Do not take Aricept Flas:
Warnings and precautions
Consult your doctor before starting to take Aricept Flas if you have or have had:
You should avoid taking Aricept Flas with other acetylcholinesterase inhibitors and other cholinergic agonists or antagonists.
Use of Aricept Flas with other medications
Inform your doctor or pharmacist if you are using, have used recently or may need to use any other medication and especially if you are taking any of the following medications:
In case of surgical intervention with general anesthesia, inform your doctor that you are taking Aricept Flas as this may affect the amount of anesthetic needed.
Aricept Flas can be used in patients with mild to moderate kidney or liver disease. Inform your doctor if you have any kidney or liver disease. Patients with severe liver disease should not take Aricept Flas.
Taking Aricept Flas with food, drinks and alcohol
Place the tablet on the tongue and let it dissolve. Swallow with or without water.
Aricept Flas should not be taken with alcohol as alcohol may modify the effect of this medication.
Pregnancy, breastfeeding and fertility
If you are pregnant or breastfeeding, think you may be pregnant or intend to become pregnant, consult your doctor or pharmacist before using this medication.
You should not take Aricept Flas if you are breastfeeding your child.
Driving and operating machinery
Your condition may affect your ability to drive or operate machinery and you should not do so unless your doctor tells you it is safe to do so. Aricept Flas may cause fatigue, dizziness, drowsiness and muscle cramps, mainly at the start of treatment or when increasing the dose. If you experience these effects, you should not drive or operate machinery.
Aricept Flas is administered orally. The tablet should be placed on the tongue and allowed to dissolve before swallowing it with or without water.
Treatment with Aricept Flas begins with a 5 mg tablet, taken once a day, at night, immediately before bedtime. After a month of treatment, your doctor may recommend an increase in dosage to 10 mg, taken once a day and at night. The maximum recommended dose is 10 mg per day.
If you experience abnormal dreams, nightmares, or difficulty sleeping (see section 4), your doctor may recommend taking Aricept Flas in the morning.
If you have mild or moderate liver disease (a disease that affects the liver) or kidney disease (a disease that affects the kidneys), you can take Aricept Flas. Inform your doctor before starting treatment if you have liver or kidney problems. Patients with severe liver disease should not take Aricept Flas.
Use in children
Aricept Flas is not recommended for use in children.
If you take more Aricept Flas than you should
If you have taken more Aricept Flas than you should, consult your doctor, pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount used.
The symptoms of overdose may include nausea (feeling sick) , vomiting (being sick) , drooling, sweating, decreased heart rate, low blood pressure (dizziness or lightheadedness when standing up), breathing difficulties, loss of consciousness, and seizures.
If you forget to take Aricept Flas
Do not take a double dose to compensate for the missed dose.
If you interrupt treatment with Aricept Flas
Do not stop taking Aricept Flas unless your doctor tells you to. If you stop taking Aricept Flas, the benefits of treatment will gradually disappear.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
The following side effects have been reported by people taking Aricept.
Contact your doctor if you experience any of these side effects during treatment with Aricept.
Severe side effects:
You should inform your doctor immediately if you notice any of the following severe side effects mentioned, as you may need urgent medical treatment.
The estimated frequency of side effects is as follows:
Very common: can affect more than 1 in 10 patients
Common: can affect between 1 and 10 of every 100 patients
Uncommon: can affect between 1 and 10 of every 1,000 patients
Rare: can affect between 1 and 10 of every 10,000 patients
Frequency unknown (cannot be estimated from available data)
Reporting side effects
If you experience any type ofsideeffects, consult your doctor or pharmacist, even if it is a side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use, Website:www.notificaRAM.es.
Keep this medication out of the sight and reach of children.
This medication does not require special storage conditions.
Do not use Aricept Flasafter the expiration date that appears on the packaging.The expiration date is the last day of the month indicated
Medicines should not be disposed of through drains or in the trash.Deposit the containers and medicines you no longer need at the SIGRE collection pointof the pharmacy.In case of doubtask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Aricept Flas 10 mg buccal tablets
Appearance of the product and content of the container
Aricept Flas 10 mg buccal tablets are available in a blister pack with a single dose size formed by PVC/PVdC/PE/PVdC/PVC with an aluminum foil on the back, containing 28 tablets.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
Responsible for manufacturing:
Fareva Amboise
Zone Industrielle
29 route des Industries
37530 Pocé-sur-Cisse
France
or
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
You can request more information about this medication by contacting the local representative of the holder of the marketing authorization:
Eisai Pharmaceutical, S.A.
Parque Empresarial Cristalia.
Calle Via de los Poblados 3, Edf. 7/8
4th floor
28033 Madrid
Phone: + (34) 91 455 94 55
Last review date of this leaflet: December 2022
“Detailed and updated information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/”
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.